Mary White Scharf
Dr. Mary E. White-Scharf is Senior Vice President of Research at
BioTransplant Incorporated, a company that is developing products to address
the current challenges in transplantation medicine. She joined the
company in 1991 as Director of Monoclonal Antibodies and led the project to
develop BTI-322®, an anti-CD2 monoclonal antibody, the humanized
version of which is currently in clinical trials for treatment of
psoriasis. In 1995, she was promoted to Vice President of Research and
assumed leadership of the XenoMune program, a system being developed to enable
transplantation of porcine organs into humans. Prior to joining
BioTransplant, Dr. White-Scharf held the position of Research Scientist at Repligen,
where she led efforts to develop monoclonal antibodies directed against the V3
loop of HIV-1.
To return to previous topic, click on your browser's 'Back' button.